


## Trimethobenzamide

Cat. No.:	HY-12751
CAS No.:	138-56-7
Molecular Formula:	C <sub>21</sub> H <sub>28</sub> N <sub>2</sub> O <sub>5</sub>
Molecular Weight:	388.46
Target:	Dopamine Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Trimethobenzamide (Ro 2-9578 free base) is a blocker of the D <sub>2</sub> receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	D <sub>2</sub> receptor <sup>[1]</sup>
<b>In Vitro</b>	Trimethobenzamide is a (non-phenothiazine) benzamide antiemetic that acts centrally to block D2 receptors, thereby inhibiting the medullary chemoreceptor trigger zone by blocking emetic impulses to the vomiting center <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	The oral bioavailability of Trimethobenzamide is 60% to 100%. The time to peak is about 45 minutes after oral administration and; Intramuscular (I.M.) administration about 30 minutes after intramuscular administration <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Smith HS, et al. Dopamine receptor antagonists. Ann Palliat Med. 2012 Jul;1(2):137-42.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA